Plus: SFP issues guidance for deep contraceptive implant removal, atogepant reduces menstrual migraine days, and FDA examines pregnancy registry enrollment.
Intuitive's da Vinci SP system received CE mark approval on September 14, 2026, for transvaginal gynecologic procedures, expanding surgical options for European clinicians. Meanwhile, the FDA is launching a project to understand struggles with pregnancy registry enrollment, impacting data-reliant maternal health stakeholders. This regulatory focus on clinical access and data collection, alongside new diagnostic and treatment protocols, shapes the landscape for femtech product development and provider practice. Five takes inside, plus a quick-hits roundup.
VIA FutureFemHealth
ProvanAI raised $1.2 million in pre-seed funding to develop AI technology predicting a woman's five-year ovarian cancer risk from a mammogram. Joy Jiang and Graham Colditz, founders from Washington University School of Medicine, previously founded Prognosia, which Lunit acquired last year. ProvanAI collects external data to validate its technology and plans to pursue FDA clearance. This advancement could offer new diagnostic tools for femtech operators and clinicians focusing on women's health.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
On September 14, 2026, Intuitive announced CE mark approval for its da Vinci SP system in Europe. The approval covers the robotic-assisted surgical system for transvaginal gynecologic procedures. This expansion of surgical technology offers new options for clinicians and providers in the femtech surgical space.
Read the full story →
— The Luteal Editorial Team
VIA STAT News
The FDA will launch a project examining why pregnancy registries struggle with enrollment. This initiative directly impacts stakeholders reliant on robust maternal health data for product development and clinical guidance.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
A new SFP Committee Statement standardizes protocols for removing deep and nonpalpable contraceptive implants. This guidance provides clinicians with updated procedures for a common gynecological and contraceptive concern.
Read the full story →
— The Luteal Editorial Team
VIA Contemporary OB/GYN
Atogepant reduced perimenstrual migraine days versus placebo in the Phase 3 LUNA study. The treatment also met all eight secondary endpoints in this study. This research offers new data for menstrual health-focused clinical development.
Read the full story →
— The Luteal Editorial Team